Novo Nordisk

Novo Nordisk Is Positioned To Profit Off Of Obesity Epidemic But Price May Be Rich

Novo Nordisk Is Positioned To Profit Off Of Obesity Epidemic But Price May Be Rich

Seeking Alpha

Novo to Hire 1,000 People in 2 Years in Emerging Markets

Novo to Hire 1,000 People in 2 Years in Emerging Markets

Bloomberg Businessweek

Novo Says It’s Likely to Benefit From Bristol-Amylin Tie-Up

Novo Says It’s Likely to Benefit From Bristol-Amylin Tie-Up

Bloomberg

NVO's Tresiba Approved in Japan

NVO's Tresiba Approved in Japan

Yahoo/Zacks

Bristol-Myers Squibb - Between Patent Deadlines And Revenue Shifts

Bristol-Myers Squibb - Between Patent Deadlines And Revenue Shifts

Seeking Alpha

Is Novo Nordisk the Perfect Stock?

Is Novo Nordisk the Perfect Stock?

Motley Fool

Novo Nordisk

Novo Nordisk halts development of hemophilia drug

Novo Nordisk halts development of hemophilia drug

Reuters

Biogen, Shire, Novo top pharma ranking of shareholder value

Biogen, Shire, Novo top pharma ranking of shareholder value

Fierce Pharma

The $47 Billion Hole in Pharma's Near-Term Future

The $47 Billion Hole in Pharma's Near-Term Future

Forbes

Novo Nordisk CFO Explains Winning Diabetes Strategy

Novo Nordisk CFO Explains Winning Diabetes Strategy

Investors.com